Skip to main content

MorphoSys Acquires Serotec for $35.3M, Expanding Research Antibody Line

NEW YORK, Jan. 12 (GenomeWeb News) - Antibody company MorphoSys has acquired privately held Serotec, an Oxford, England-based supplier of antibodies for research applications, the companies said today.

 

Munich, Germany-based MorphoSys will pay a total of £20 million ($35.3 million) for Serotec, with £14 million of that amount paid in cash and the remainder paid through the issuance of 208,560 new shares, the companies said.

 

Serotec will become a subsidiary of MorphoSys and will continue to sell its products to the research market, according to the statement. The acquisition, which is intended to expand the company's research antibody business, will give MorphoSys a distribution network in the United States, the United Kingdom, France, and Scandinavia, the companies said.

 

MorphoSys' January 2005 acquisition of Biogenesis was also intended to expand its research antibody business.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.